Right Now on Amazon - 2 items found

Price: $28.95
Yahoo answers: Can fabry's disease prevent you from joining the national guard?
-
I'm looking to join the national guard, but I have fabry's disease. It's not severe but I take treatment and I'm wondering if it will effect their willingness to let me join.
05/30/13
Latest news about treatment for fabry disease
-
Amicus Therapeutics (FOLD) Announces Positive Migalastat Phase 3 Data in ...
These positive results shown for the first time today in both naïve and ERT switch patients add to the totality of the data that suggest migalastat could be an important new therapy in the treatment of Fabry disease. These data also continue to show
Source: http://www.streetinsider.com/Corporate%2BNews/Amicus%2BTherapeutics%2B(FOLD)%2BAnnounces%2BPositive%2BMigalastat%2BPhase%2B3%2BData%2Bin%2BFabry%2BDisease/10245795.html -
Protalix Finishes Patient Enrollment for Fabry Disease Study
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight
Source: http://www.zacks.com/stock/news/163142/protalix-finishes-patient-enrollment-for-fabry-disease-study -
Protalix Bio up on positive interim data for Fabry disease candidate (PLX)
is up 7% premarket on above average volume in response its announcement of additional positive interim data from its Phase 1/2 dose-ranging study of the recombinant human alpha-Galactosidase-A enzyme, PRX-102, for the treatment of Fabry disease.
Source: http://seekingalpha.com/news/2294746-protalix-bio-up-on-positive-interim-data-for-fabry-disease-candidate -
Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of ...
CARMIEL, Israel, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company has completed enrollment in its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease.
Source: http://www.nasdaq.com/press-release/protalix-biotherapeutics-completes-enrollment-in-phase-iii-clinical-trial-of-prx102-for-fabry-20150202-00179 -
Genzyme biologics plant continues to pay off for Sanofi
driven in large part by a 22% growth in sales at Boston-based Genzyme. The biotech's revenue leap was powered in part by sales of drugs like Fabrazyme. The treatment for the rare Fabry disease saw 2014 sales soar 23% to €460 million ($521.7 million).
Source: http://www.fiercepharmamanufacturing.com/story/genezyme-biologics-plant-continues-pay-sanofi/2015-02-12
Images treatment for fabry disease





http://www.uptodate.com/contents/treatment-of-fabry-disease
http://www.medicinenet.com/fabrys_disease/article.htm
http://www.webmd.com/a-to-z-guides/fabry-disease
http://en.wikipedia.org/wiki/Fabry_disease
http://www.medicinenet.com/fabrys_disease/page2.htm